Results 11 to 20 of about 95 (52)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.

JAMA Netw Open, 2022
Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ, NorthStar UK Network and CINRG DNHS Investigators.   +27 more
europepmc   +1 more source

Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy. [PDF]

Sci Rep
Tobin RA, Dang UJ, Hagerty L, Ward LM, Rooman R, Konopka KH, Clemens PR, Guglieri M, Damsker J, Ziemba M, Hathout Y, Hoffman EP.   +11 more
europepmc   +1 more source

(3β,16α)-3,16-Dihydroxypregn-5-en-20-one from the Twigs of Euonymus alatus (Thunb.) Sieb. Exerts Anti-Inflammatory Effects in LPS-Stimulated RAW-264.7 Macrophages. [PDF]

Molecules, 2019
Lee S, Lee D, Baek SC, Jo MS, Kang KS, Kim KH.   +5 more
europepmc   +1 more source

Vamorolone Safety, Pharmacokinetics, and Exploratory Efficacy in Duchenne Muscular Dystrophy: A Phase II, Nonrandomized, Multiple-Dose Study in 2-<4-Year-Old Boys. [PDF]

Neurology
Mah JK, Gonorazky HD, Nigro E, Lochmüller H, Alemán A, Yaworski A, Oskoui M, Sbrocchi AM, Selby KA, de Vera A, Mathur R, Gresko E, Linden A, Dutreix C, Hoffman EP.   +14 more
europepmc   +1 more source

Reply: To PMID 25174863. [PDF]

J Allergy Clin Immunol, 2015
Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, Irvin CG, Mohapatra S, Peters SP, Rayapudi S, Sugar EA, Wise RA, American Lung Association–Asthma Clinical Research Centers.   +11 more
europepmc   +1 more source

Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial. [PDF]

Neurology
Clemens PR, Berglund A, Schiava M, James MK, McDermott MP, Bushby K, Lampa E, Rochford ETJ, Ward LM, Griggs RC, Hoffman EP, Guglieri M.   +11 more
europepmc   +1 more source

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy. [PDF]

J Neurol
Lochmüller H, Gonorazky H, Nigro E, Mah JK, Alemán A, Yaworski A, Oskoui M, Sbrocchi AM, Selby K, de Vera A, McAdam L, Gresko E, Linden A, Dutreix C, Hoffman EP.   +14 more
europepmc   +1 more source

Regimen-dependent glucocorticoid effects improve muscle performance without altering CNS physiology in mdx mice. [PDF]

J Physiol
Major GS, Chen J, van den Berg E, Merry DL, Lindsay A.   +4 more
europepmc   +1 more source

Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects. [PDF]

Rheumatology (Oxford)
Crastin A, Shanker A, Sagmeister MS, Taylor A, Lavery GG, Raza K, Hardy RS.   +6 more
europepmc   +1 more source

Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy. [PDF]

Neurol Sci
Ibrahim MS, Abdelwahab OA, Elawfi B, Ali FY, Amro S, Mohammed SF, Shaheen N, Negida A, Arndt M, Hijazi MM, Schaefer J, Siepmann T.   +11 more
europepmc   +1 more source